GALC and Guillain-Barre syndrome: As shown in Table S3, the frequency of antibodies against glycolipids and glycolipids complex in 150 of patients with GBS was anti‐GM1 (39%), anti‐GM1b (1%), anti‐GD1a (11%), anti‐GD1b (19%), anti‐GalNAc‐GD1a (11%), anti‐GQ1b (13%), anti‐GM1:GalC complex (23%), anti‐GM1:sulfatide complex (20%), and anti‐GalC:sulfatide complex (1%), respectively.